StockNews.AI
NEO
StockNews.AI
6 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO

1. Pomerantz LLP investigates potential securities fraud by NeoGenomics. 2. NeoGenomics reported Q2 2025 revenue of $181.3 million, below expectations. 3. Company reduced 2025 revenue forecast to $720-$726 million from $753 million. 4. NeoGenomics stock fell 18.73% following disappointing financial results. 5. Class action potential raises concerns among investors regarding company governance.

4m saved
Insight
Article

FAQ

Why Bearish?

The significant revenue miss and stock price decline suggest a loss of investor confidence, leading to bearish sentiment. Historical examples show similar situations have often resulted in prolonged stock downturns, especially if fraud investigations persist.

How important is it?

The investigation and significant revenue shortfall signal serious governance concerns, which are critical for investor trust. Poor financial performance and legal troubles typically indicate a volatile stock price, heightening investor caution.

Why Short Term?

Immediate investor reactions are likely negative due to news of fraud investigations and financial misses. Previous similar events in companies typically saw impacts within weeks to months.

Related Companies

GENETECEXASMYGNBPCCDXS
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether NeoGenomics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] July 29, 2025, NeoGenomics issued a press release reporting its financial results for the second quarter of 2025.  Among other items, NeoGenomics reported revenue of $181.3 million, falling short of consensus estimates, and a net loss of $45.1 million.  NeoGenomics also reduced its 2025 revenue forecast to a range of $720 million to $726 million, down from a previous estimate of approximately $753 million.  In addition, NeoGenomics lowered its adjusted EBITDA projection to a range of $41 million to $44 million from a prior range of $55 million to $58 million.  On this news, NeoGenomics’ stock price fell $1.21 per share, or 18.73%, to close at $5.25 per share on July 29, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.    CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News